Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT04742283 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

323

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Open Angle Glaucoma
Ocular Hypertension

Interventions

DRUG: DE-126 Ophthalmic Solution 0.002% QD
DRUG: Timolol Maleate Ophthalmic Solution 0.5% BID

Sponsor

Santen Inc.